No Free Lunch, G20 Health Ministers Find At First Meeting 20/05/2017 Monika Ermert Group of 20 health ministers today finished their first joint table top exercise to simulate the outbreak of a new deadly viral pandemic in “Anycountry” and passed a seven-page final resolution on pandemic preparedness and antimicrobial resistance. Non-governmental experts and health organizations welcomed the first ever meeting of health ministers in the G20 format, but see a risk of framing the debate from a global North security perspective. And despite a call of urgency with regard to antimicrobial resistance, the G20 could not agree to include the de-linking of the cost of investment in R&D from the price of medical products. Continue reading -> G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 Monika Ermert Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow. Continue reading -> IP-Watch Guide To 2017 World Health Assembly: Election, Budget, Antibiotics, Cancer, R&D And More 16/05/2017 Catherine Saez In a few days, the 70th World Health Assembly will open its doors in Geneva with a marathon agenda, and over 4,000 registered delegates. The election of a new director general, the approval of the budget for the next biennium (2018/2019) are set to capture the attention of member states. However, many other subjects require their consideration, such as a resolution on cancer treatment costs, research and development for epidemic diseases, for new antibiotics, for medicines affecting primarily poor populations, access to medicines, and the influenza pandemic preparedness framework. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 Monika Ermert Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow. Continue reading -> IP-Watch Guide To 2017 World Health Assembly: Election, Budget, Antibiotics, Cancer, R&D And More 16/05/2017 Catherine Saez In a few days, the 70th World Health Assembly will open its doors in Geneva with a marathon agenda, and over 4,000 registered delegates. The election of a new director general, the approval of the budget for the next biennium (2018/2019) are set to capture the attention of member states. However, many other subjects require their consideration, such as a resolution on cancer treatment costs, research and development for epidemic diseases, for new antibiotics, for medicines affecting primarily poor populations, access to medicines, and the influenza pandemic preparedness framework. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
IP-Watch Guide To 2017 World Health Assembly: Election, Budget, Antibiotics, Cancer, R&D And More 16/05/2017 Catherine Saez In a few days, the 70th World Health Assembly will open its doors in Geneva with a marathon agenda, and over 4,000 registered delegates. The election of a new director general, the approval of the budget for the next biennium (2018/2019) are set to capture the attention of member states. However, many other subjects require their consideration, such as a resolution on cancer treatment costs, research and development for epidemic diseases, for new antibiotics, for medicines affecting primarily poor populations, access to medicines, and the influenza pandemic preparedness framework. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy